血清NLR、PLR与非小细胞肺癌预后相关性研究进展  

Research progresses on the correlation between serum NLR,PLR and the prognosis of non-small cell lung cancer

作　　者：周海英 郭冉 赵聪[2] 吴培培[2] 陈卫东[2] 孙宗文[2] ZHOU Haiying;GUO Ran;ZHAO Cong;WU Peipei;CHEN Weidong;SUN Zongwen(Clinical Medical College of Jining Medical College,Jining 272000,China;Department of Oncology,Jining First People's Hospital,Jining 272000,China)

机构地区：[1]济宁医学院临床医学院,山东济宁272000 [2]济宁市第一人民医院肿瘤科,山东济宁272000

出　　处：《山东第一医科大学（山东省医学科学院）学报》2023年第2期147-151,共5页Journal of Shandong First Medical University ＆ Shandong Academy of Medical Sciences

摘　　要：非小细胞肺癌(non-small cell lung cancer,NSCLC)患者的预后主要取决于其TNM分期、年龄、身体状况、合并症等,然而相似状态和相同分期的患者经过临床规范治疗后,患者生活质量和生存期仍有不同。血小板与淋巴细胞比值(platelet to lymphocyte ratio,PLR)、中性粒细胞与淋巴细胞比值(neutrophil to lymphocyte ratio,NLR)是机体系统性炎症指标,在NSCLC的发生发展中有重要作用,其变化与NSCLC的预后相关。目前已经有大量文章报道了PLR和/或NLR与NSCLC患者的预后关系,因此,本文就此进行综述,为临床诊疗及患者预后判断提供新思路。The prognosis of patients with non-small cell lung cancer(NSCLC)mostly depends on the TNM stage,age,physical condition,comorbidities,etc.However,after standard clinical treatment,the quality of life and the survival of patients with similar status and the same stage are still different.Platelet to lymphocyte ratio(PLR)and neutrophil to lymphocyte ratio(NLR)represent biomarkers of systemic inflammation,which play important roles in the occurrence and development of NSCLC.The changes of NLR and PLR are associated with the prognosis of NSCLC.At present,a large number of articles have introduced the relationship between PLR and/or NLR and the prognosis of NSCLC patients.Therefore,this issue has been review in order to provide ideas for clinical diagnosis and treatment and the prognosis judgment of patients.

关 键 词：中性粒细胞与淋巴细胞比值 血小板与淋巴细胞比值 非小细胞肺癌 预后 

分 类 号：R734.2[医药卫生—肿瘤]